Subclassification into these entities is important to evaluate prognosis and treatment options, as some subtypes, such as diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2), have worse prognosis and require alternative treatment regimens.1 This evidence concerns the gene MYC and diffuse large B-cell lymphoma.